Other safety alerts
|
| |
| Singapore: Caution on the use of lysozyme-containing products in patients with known egg allergy |
| |
Health Sciences Authority (HSA) would like to inform healthcare professionals that lysozyme that is present in lysozyme-containing therapeutic products is derived from egg white, and hence these products have the potential to cause allergic reactions in patients with egg allergies. HSA has recently received an adverse drug reaction (ADR) report of severe cough, urticaria and eczema flare in a child with known egg allergy who was given lysozyme. To date, other ADRs reported with lysozyme-containing products were mainly eye swelling and rashes. HSA will be working with the companies’ marketing lysozyme-containing products to update the respective product information labels on this safety information.
Healthcare professionals are advised to check with their patient for any history of egg allergy before prescribing or dispensing lysozyme-containing products to their patients. They are also encouraged to report any suspected serious ADRs related to these products to the Vigilance and Compliance Branch of HSA.
Please refer to the following website in HSA for details:
http://www.hsa.gov.sg/content/hsa/../caution-on-the-useoflysozymecontainingproductsinpatientswithknow.html
In Hong Kong, there are 253 registered pharmaceutical products containing lysozyme. So far, the Department of Health (DH) has not received any case of adverse drug reaction related to lysozyme. In light of the above HSA’s announcement, letters to inform local healthcare professionals of the above safety information will be issued. DH will remain vigilant on safety update of the drug issued by other overseas drug regulatory authorities.
Ends/Friday, May 18, 2018
Issued at HKT 16:00
|
| |
|
